Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...

Boys who stopped ADHD treatment at higher risk for negative consequences. Oct. 16, 2012 — -- Young boys who discontinue treatment for attention deficit hyperactivity disorder (ADHD) are featured ...

With an expiration date still more than a year away, here's what the latest details reveal.

ADHD New Zealand spokesperson Darrin Bull joins Mike Hosking to discuss the significant prescription law change that will make ADHD treatment easier to acc ...

Shorter wait times and lower costs. That’s what people with ADHD and their families can expect now Victorian GPs are getting ...

General practitioners in Victoria will soon be able to diagnose and treat ADHD in adults and children in a move the state ...